Millstone Evans Group, LLC Tempest Therapeutics, Inc. Transaction History
Millstone Evans Group, LLC
- $147 Billion
- Q4 2024
A detailed history of Millstone Evans Group, LLC transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Millstone Evans Group, LLC holds 800 shares of TPST stock, worth $720. This represents 0.0% of its overall portfolio holdings.
Number of Shares
800Holding current value
$720% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TPST
# of Institutions
36Shares Held
2.29MCall Options Held
44.9KPut Options Held
109K-
Black Rock Inc. New York, NY550KShares$495,2160.0% of portfolio
-
Altium Capital Management LP New York, NY545KShares$490,5000.27% of portfolio
-
Geode Capital Management, LLC Boston, MA220KShares$198,0600.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA176KShares$158,5730.0% of portfolio
-
Fil LTD Hamilton, D0130KShares$116,6210.0% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $9.38M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...